PTCT PTC Therapeutics, Inc.

NASDAQ
$60.99

PTC Therapeutics, Inc. (PTCT) is confirmed to report earnings on October 29, 2026, after the market close. The consensus earnings estimate is $0.17 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -14.0% since its last earnings release on July 30, 2026.

PTC Therapeutics Beat Expectations, Raises Guidance
Thursday, July 30, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 29
Thursday · 4:00 PM ET
Earnings Whisper
-
vs $0.17
Rev est $311.08M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $67.20

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About PTC Therapeutics, Inc.

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.